OBJECTIVE: We evaluated the efficacy and toxicity of combined paclitaxel and cisplatin chemotherapy in patients with cancer of unknown primary site (CUP). Efficacy was evaluated in terms of response rate, progression-free survival and overall survival. METHODS: Thirty-seven patients with CUP were enrolled between January 2001 and September 2003 at Korea Cancer Center Hospital. The patients received 21-day cycles of paclitaxel (175 mg/m(2) i.v.) with cisplatin (60 mg/m(2) i.v.) given on the first day. RESULTS: Of the 37 patients, 31 had adenocarcinoma subtypes. The overall response rate of 26 patients with measurable lesions was 42% [95% confidence interval (CI) 23-61%]. Stable disease was seen in six patients and progressive disease in nine. Median time to progression was 4 months (95% CI 1.3-6.8). Median overall survival was 11 months (95% CI 8.3-13.5). The major toxicities were neuropathy and neutropenia. Grade 4 neutropenia occurred in 10 patients, but febrile neutropenia was seen in four. CONCLUSIONS: This combined paclitaxel and cisplatin regimen was well tolerated with an encouraging level of effectiveness for patients with CUP.
OBJECTIVE: We evaluated the efficacy and toxicity of combined paclitaxel and cisplatin chemotherapy in patients with cancer of unknown primary site (CUP). Efficacy was evaluated in terms of response rate, progression-free survival and overall survival. METHODS: Thirty-seven patients with CUP were enrolled between January 2001 and September 2003 at Korea Cancer Center Hospital. The patients received 21-day cycles of paclitaxel (175 mg/m(2) i.v.) with cisplatin (60 mg/m(2) i.v.) given on the first day. RESULTS: Of the 37 patients, 31 had adenocarcinoma subtypes. The overall response rate of 26 patients with measurable lesions was 42% [95% confidence interval (CI) 23-61%]. Stable disease was seen in six patients and progressive disease in nine. Median time to progression was 4 months (95% CI 1.3-6.8). Median overall survival was 11 months (95% CI 8.3-13.5). The major toxicities were neuropathy and neutropenia. Grade 4 neutropenia occurred in 10 patients, but febrile neutropenia was seen in four. CONCLUSIONS: This combined paclitaxel and cisplatin regimen was well tolerated with an encouraging level of effectiveness for patients with CUP.
Authors: K B Pittman; I N Olver; B Koczwara; D Kotasek; W K Patterson; D M Keefe; C S Karapetis; F X Parnis; S Moldovan; S J Yeend; T J Price Journal: Br J Cancer Date: 2006-10-31 Impact factor: 7.640
Authors: G Huebner; H Link; C H Kohne; M Stahl; A Kretzschmar; S Steinbach; G Folprecht; H Bernhard; S E Al-Batran; P Schoffski; C Burkart; F Kullmann; B Otremba; M Menges; M Hoffmann; U Kaiser; A Aldaoud; A Jahn Journal: Br J Cancer Date: 2008-12-09 Impact factor: 7.640
Authors: K Yonemori; M Ando; M Yunokawa; T Hirata; T Kouno; C Shimizu; K Tamura; N Katsumata; A Hirakawa; K Matsumoto; Y Yamanaka; H Arioka; Y Fujiwara Journal: Br J Cancer Date: 2008-12-16 Impact factor: 7.640
Authors: Rocío Grajales-Álvarez; Ana Martin-Aguilar; Juan A Silva; Jaime G De La Garza-Salazar; Erika Ruiz-García; César López-Camarillo; Laurence A Marchat; Horacio Astudillo-De La Vega Journal: Mol Clin Oncol Date: 2017-04-06